公开(公告)号：US20240279201A1

公开(公告)日：2024-08-22

申请号：US18565426

申请日：2022-06-01

申请人： Fengtian Xue ,  Yan Shu ,  Yong Ai

发明人： Fengtian Xue ,  Yan Shu ,  Yong Ai

IPC分类号： C07D401/12 ,  A61K31/423 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/517 ,  A61K31/69 ,  A61K45/06 ,  A61K47/55 ,  A61K47/60 ,  A61P1/16 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F5/02

CPC分类号： C07D401/12 ,  A61K31/423 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/517 ,  A61K31/69 ,  A61K45/06 ,  A61K47/551 ,  A61K47/60 ,  A61P1/16 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F5/025

摘要： Compounds and compositions are provided as inhibitors of the Wnt/beta-catenin pathway and/or activators of the adenosine monophosphate-activated kinase (AMPK) pathway for the treatment of diseases that implicate the same. Such diseases include cancer or a metabolic disease. Cancers that may be treated by these compounds and compositions include adrenocortical cancer, hepatocellular cancer, hepatoblastoma, malignant melanoma, ovarian cancer, Wilm's tumor, Barrett's esophageal cancer, prostate cancer, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, bladder cancer, breast cancer (e.g. triple negative breast cancer), gastric cancer, head & neck cancer, lung cancer, mesothelioma, cervical cancer, uterine cancer, myeloid leukemia cancer, lymphoid leukemia cancer, pilometricoma cancer, medulloblastoma cancer, glioblastoma, and familial adenomatous polyposis. Metabolic diseases include type 2 diabetes, obesity, hyperlipidemia, alcoholic or non-alcoholic fatty liver disease, and liver fibrosis.